Lantheus Holdings, Inc. $LNTH Stake Lifted by Eagle Global Advisors LLC

Key Points

• Eagle Global Advisors LLC increased its stake in Lantheus Holdings by 90.3% during the second quarter, owning 181,150 shares valued at approximately $14.8 million.
• Analyst recommendations for Lantheus have varied, with target prices now ranging from $63 to $84, and a overall consensus rating of "Moderate Buy."
• Lantheus stock recently declined by 1.7%, trading at around $50.61, down from a one-year high of $118.21.

Eagle Global Advisors LLC raised its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 90.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 181,150 shares of the medical equipment provider's stock after purchasing an additional 85,970 shares during the quarter. Eagle Global Advisors LLC owned 0.26% of Lantheus worth $14,829,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the business. Signaturefd LLC increased its stake in shares of Lantheus by 36.5% in the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 116 shares in the last quarter. Quarry LP lifted its stake in shares of Lantheus by 2,350.0% during the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider's stock worth $48,000 after purchasing an additional 470 shares during the last quarter. Hughes Financial Services LLC acquired a new stake in Lantheus in the first quarter valued at approximately $81,000. UMB Bank n.a. grew its stake in shares of Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Lantheus by 117.7% in the 1st quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock valued at $114,000 after purchasing an additional 633 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on LNTH shares. B. Riley dropped their target price on Lantheus from $109.00 to $84.00 and set a "buy" rating on the stock in a report on Tuesday, September 16th. Mizuho dropped their price target on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. JMP Securities reduced their price objective on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a "hold" rating in a research report on Monday, August 11th. Finally, TD Cowen decreased their price target on shares of Lantheus from $95.00 to $80.00 and set a "buy" rating on the stock in a research note on Monday, September 15th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.50.

Lantheus Stock Down 1.7%

Shares of Lantheus stock opened at $50.61 on Friday. The stock has a 50-day moving average price of $58.41 and a 200 day moving average price of $78.05. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The company has a market cap of $3.44 billion, a P/E ratio of 13.46 and a beta of 0.15. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The business had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the prior year, the firm posted $1.80 earnings per share. The business's revenue was down 4.1% on a year-over-year basis. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,812,000 shares of company stock valued at $382,427,380 over the last three months. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.